Medical Device Registration in the Middle East: Saudi SFDA, UAE & GCC Guide

Why the Middle East Matters for Medical Device Manufacturers

The Middle East medical device market has grown from a niche consideration to a strategic priority for manufacturers worldwide. The Gulf Cooperation Council (GCC) states — Saudi Arabia, the United Arab Emirates (UAE), Kuwait, Bahrain, Qatar, and Oman — represent the economic core of this opportunity. Combined healthcare spending across the GCC exceeded $90 billion in 2025, with medical devices accounting for an estimated $12-14 billion and growing at 7-9% annually. Saudi Arabia alone accounts for roughly half of that figure.

Three forces are driving this growth. First, massive government investment in healthcare infrastructure. Saudi Arabia's Vision 2030 program has committed hundreds of billions of dollars to healthcare transformation, including new hospitals, specialty centers, and digital health platforms. The UAE's healthcare sector is expanding to support both its domestic population and its ambitions as a medical tourism hub. Second, demographic and epidemiological trends — a young but rapidly urbanizing population with rising rates of diabetes, cardiovascular disease, and obesity — are driving demand for medical technologies from glucose monitors to cardiac implants. Third, regulatory maturation. Countries that once relied on minimal import controls have built sophisticated regulatory frameworks, often modeled on international best practices and increasingly aligned with IMDRF guidance.

For foreign manufacturers, the Middle East offers real revenue — but the regulatory landscape is more fragmented and more complex than it appears from a distance. Saudi Arabia and the UAE each have their own regulatory systems. The GCC has a mutual recognition framework that works in theory but has practical limitations. And the smaller Gulf states each impose their own requirements, some well-defined and others less so.

This guide covers everything you need to register medical devices across the Middle East: the Saudi SFDA system in detail, the UAE's multi-regulator framework, GCC harmonization, IVD-specific requirements, post-market obligations, and practical market entry strategies.

Saudi Arabia: SFDA Medical Device Registration

Overview of the SFDA

The Saudi Food and Drug Authority (SFDA) is the national regulatory authority responsible for medical devices, pharmaceuticals, food safety, and cosmetics in the Kingdom of Saudi Arabia. Established in 2003 and operational since 2009 for medical devices, the SFDA has developed into one of the most structured and demanding regulatory bodies in the Middle East. It is increasingly recognized internationally — the SFDA became an IMDRF affiliate member in 2017 and was elevated to full management committee member in 2022, signaling its growing alignment with global regulatory practices.

The SFDA's Medical Devices Sector (MDS) administers all aspects of device regulation, including product registration, establishment licensing, post-market surveillance, adverse event reporting, and field safety corrective actions.

SFDA Classification System

Saudi Arabia uses a four-class risk-based classification system that closely mirrors the EU MDR and GHTF/IMDRF classification frameworks.

SFDA Class	Risk Level	Description	Examples
Class A	Low	Devices that pose minimal risk to the patient and user	Tongue depressors, examination gloves, reusable surgical instruments, stethoscopes
Class B	Low-Moderate	Devices with a moderate degree of risk, typically non-invasive or short-term invasive	Hypodermic needles, suction equipment, infusion sets, powered wheelchairs, ultrasound imaging systems
Class C	Moderate-High	Devices with an elevated risk, including medium- to long-term invasive devices	Orthopedic implants (screws, plates), ventilators, hemodialysis equipment, contact lenses, urethral catheters
Class D	High	Devices that sustain life, are long-term implantable, or present a significant risk of illness or injury	Cardiovascular stents, pacemakers, heart valves, defibrillators, total joint replacements, drug-eluting devices

Within Class A, the SFDA recognizes important sub-classifications that carry additional requirements beyond standard Class A devices:

SFDA Sub-Class	EU MDR Equivalent	Additional Requirements
Class A — Sterile	Class Is	Sterility validation, sterilization process documentation required
Class A — Measuring function	Class Im	Metrological traceability, measurement accuracy validation required
Class A — Reusable surgical instruments	Class Ir	Reprocessing validation, material compatibility documentation required

These sub-classifications are significant because sterile, measuring, and reusable surgical Class A devices require more extensive documentation than standard Class A devices — including involvement of quality management system assessment that goes beyond the basic Class A listing process. The SFDA charges the same fee (SAR 15,000) for all Class A sub-types.

Classification is the manufacturer's initial responsibility, subject to SFDA review and potential reclassification. The SFDA charges SAR 1,000 for each formal classification application submitted through the GHAD system. The SFDA's classification rules draw heavily on the GHTF classification framework (SG1/N77:2012), supplemented by SFDA-specific guidance documents. Manufacturers should reference the SFDA's Medical Device Classification Database and the published classification guidance on the SFDA website for definitive classification decisions.

Practical tip: If you already hold EU MDR CE marking, your EU classification will generally correspond to the SFDA class — Class I to A, IIa to B, IIb to C, III to D. However, do not assume automatic equivalence. The SFDA reserves the right to reclassify devices, and certain device types (particularly software and combination products) may be classified differently. Always confirm classification with the SFDA or your Saudi authorized representative before beginning the registration process.

MDMA — Medical Device Marketing Authorization

The Medical Device Marketing Authorization (MDMA) is the core product registration pathway for medical devices in Saudi Arabia. Since the SFDA's electronic system overhaul in 2021, MDMA has replaced the older product listing process as the primary market authorization mechanism for Class B, C, and D devices.

Evolution of SFDA Registration Pathways

Understanding the history of SFDA registration pathways is important because older guidance and outdated articles still reference legacy routes that no longer exist:

• MDNR (Medical Device National Registry) — Canceled September 2022. The MDNR was a simplified listing pathway for non-sterile, non-measuring, low-risk (Class A) medical devices. It did not require a full technical file or an authorized representative. The SFDA canceled MDNR in September 2022, requiring all devices — including low-risk Class A — to go through the MDMA pathway with a complete technical file and an appointed AR.

• MDMA 1 (GHTF Route) — Canceled end of 2021. Under MDMA 1, the SFDA accepted approvals from GHTF member countries (EU, US, Canada, Australia, Japan) as the primary basis for registration. This was a faster, lighter pathway with minimal technical file review. The SFDA canceled MDMA 1 at the end of 2021.

• MDMA 2 (Technical File Application / TFA) — Active since January 2022. MDMA 2 is now the sole registration pathway for all medical devices and IVDs in Saudi Arabia. It requires submission of a complete technical file — similar in scope and depth to an EU MDR technical documentation package. CE marking or FDA approval is not a prerequisite; instead, the SFDA conducts its own independent evaluation based on the submitted technical file. Prior reference market approvals (FDA, EU, Health Canada, TGA, PMDA) can still support the application and may reduce review scrutiny, but they do not substitute for the full technical file.

Important note: Many online guides and older regulatory consultancy materials still reference the GHTF/MDMA 1 pathway as if it were active. It is not. Since January 2022, all SFDA registrations require a full technical file under MDMA 2. Manufacturers who assume they can register in Saudi Arabia based solely on their FDA clearance or CE certificate — without preparing a complete Saudi-specific technical file — will be rejected.

MDMA Application Requirements

An MDMA application is submitted electronically through the SFDA's online portal (GHAD system) and must include:

1. Administrative Information

• Manufacturer name, address, and contact details
• Saudi Authorized Representative (SAR) information and authorization letter
• Device trade name, model numbers, and generic device description
• SFDA device classification and applicable product code
• GMDN code or UMDNS code

2. Quality Management System Evidence

• ISO 13485 certificate (from an accredited certification body)
• MDSAP certificate (accepted and increasingly encouraged)
• Quality management system summary

3. Regulatory Approval Evidence from Reference Markets

• FDA 510(k) clearance, PMA approval, or De Novo classification
• EU MDR CE certificate (from an EU-recognized Notified Body)
• Other reference market approvals: Health Canada, TGA (Australia), PMDA (Japan)

4. Technical Documentation

• Device description, intended use, and indications for use
• Principles of operation and mechanism of action
• Materials and biocompatibility data (including biological evaluation per ISO 10993)
• Design verification and validation summaries
• Software documentation (for devices with software, including IEC 62304 compliance evidence)
• Sterility and packaging validation (for sterile devices)
• Electrical safety data (IEC 60601-1 series, where applicable)
• Shelf life and stability data
• Labeling — including Arabic language labeling requirements

5. Clinical Evidence

• Clinical evaluation report (CER) or summary of clinical evidence
• Clinical investigation data (where applicable)
• Literature reviews and post-market clinical follow-up data

6. Risk Management

• Risk management file per ISO 14971
• Summary of risk analysis, risk evaluation, and residual risk assessment

7. Instructions for Use and Labeling

• IFU in English and Arabic
• Device labeling with Arabic translation
• Symbols per ISO 15223-1

8. Essential Principles of Safety and Performance (EPSP)

• Compliance checklist demonstrating conformity with each applicable Essential Principle (as specified in MDS-REQ 1, Annex 1 and Annex 2)
• For each Essential Principle, identification of the standards applied, method of conformity, and specific supporting documents
• The EPSP checklist is a core component of the SFDA technical file and must be completed for every MDMA application

Practical tip: The SFDA's Essential Principles framework is closely modeled on the IMDRF Essential Principles (IMDRF/GRRP WG/N47) and the EU MDR General Safety and Performance Requirements (Annex I). If you have already completed an EU MDR GSPR checklist, you can adapt it for the SFDA EPSP checklist — the structure and content requirements are highly similar, though the SFDA may require Saudi-specific considerations for certain principles.

Device Bundling — Grouping Multiple Devices in One MDMA Application

The SFDA permits manufacturers to bundle up to 50 devices in a single MDMA application, provided the devices meet specific grouping criteria. This can significantly reduce registration costs and administrative burden for manufacturers with broad product portfolios.

Bundling Type	Criteria	Examples
Single Product	Same device sold in multiple sizes or models with identical intended use	Syringes with different volumes
Family	Devices with the same risk class, manufacturer, design, and intended use	Catheters of varying lengths
System	Devices intended to operate together for a common purpose	ECG machine + electrodes + leads
Set	Devices packaged together and intended for a common medical purpose	Surgical kits, dental kits
Software Suite	Related software modules operating as part of the same platform	Hospital management or imaging analysis software modules
IVD Bundle	Same risk class, manufacturer, design, and intended use	Blood collection tubes, culture media

Bundled devices share a single MDMA application fee, making this a cost-effective strategy for manufacturers with multiple related products. However, all devices in a bundle must share the same legal manufacturer, risk class, and intended use category.

MDMA Review Tracks

The SFDA operates multiple review tracks depending on the device classification and whether the device has prior approvals in recognized reference markets.

Review Track	Applicable Devices	Typical Timeline	Description
Expedited / Abridged	Class B, C, D devices with FDA or EU MDR approval	30–90 days	Relies heavily on reference market approvals. Reduced documentation review. Available for devices with valid FDA clearance/approval or EU MDR CE marking.
Standard	Class B, C, D devices without recognized reference approval	90–180 days	Full technical documentation review. Required for devices without FDA/EU approval or from non-reference regulatory systems.
Class A Listing	Class A (low risk) devices	15–30 days	Simplified notification. Manufacturer/SAR lists the device on the SFDA system with basic information. No full technical review.

Practical tip: The abridged pathway makes a significant difference. If you have FDA clearance or EU MDR CE marking, lead with those approvals. The SFDA explicitly recognizes FDA, EU MDR, Health Canada, TGA, and PMDA as reference authorities. Having one of these approvals can cut your SFDA review timeline by more than half and substantially reduce the documentation burden. If you hold approvals from none of these, expect a longer, more intensive review.

Manufacturing Site Licensing

The SFDA requires that manufacturing facilities meet Good Manufacturing Practice (GMP) standards. The SFDA's approach to GMP verification has evolved:

• ISO 13485 certification from an accredited certification body is required for all manufacturers.
• MDSAP certification is recognized and increasingly preferred. Manufacturers with MDSAP certificates may be exempt from separate SFDA facility inspections.
• SFDA facility inspections — The SFDA conducts manufacturing site inspections, particularly for Class C and D devices and for manufacturers in countries that are not part of recognized mutual recognition arrangements. These inspections may be conducted prior to initial MDMA approval or during post-market surveillance.
• Local manufacturing incentives — Saudi Arabia is actively encouraging local medical device manufacturing as part of Vision 2030. The National Industrial Development and Logistics Program (NIDLP) and the Saudi Authority for Industrial Cities and Technology Zones (MODON) offer incentives for manufacturers establishing production facilities in Saudi Arabia.

SFDA Product Listing

All medical devices marketed in Saudi Arabia must be listed in the SFDA's product listing database, regardless of class. For Class A devices, the listing process is relatively straightforward — it functions as a notification. For Class B, C, and D devices, the product listing is an outcome of the MDMA approval; once the MDMA is granted, the device is listed in the SFDA database.

Each listed device receives a unique SFDA listing number. This number is required for customs clearance at Saudi ports of entry and is used throughout the supply chain for traceability.

Clinical Evidence Requirements

The SFDA's clinical evidence expectations have increased significantly in recent years, converging toward EU MDR standards.

Device Class	Clinical Evidence Requirement
Class A	Minimal. Literature-based justification typically sufficient.
Class B	Clinical evaluation report required. Literature review typically accepted. Clinical investigations not usually required if equivalent device data is available.
Class C	Clinical evaluation report required with substantive clinical data. Clinical investigation data may be required for novel devices or new indications. Post-market clinical follow-up (PMCF) plan required.
Class D	Comprehensive clinical evidence required, including clinical investigation data for novel devices. Literature review alone typically insufficient for novel Class D devices. PMCF plan and periodic safety update reports required.

The SFDA accepts clinical data generated outside Saudi Arabia, provided the studies were conducted in accordance with ISO 14155 (or equivalent, such as FDA 21 CFR Part 812 for IDE studies) and are relevant to the Saudi patient population. However, the SFDA may request additional clinical data specific to the Saudi or Middle Eastern population for devices where ethnic, genetic, or environmental factors may influence safety or performance.

For devices with existing FDA or EU approvals, the clinical evaluation report and clinical data submitted to those authorities is generally accepted by the SFDA, subject to review.

Local Authorized Representative (Saudi Authorized Representative — SAR)

Every foreign manufacturer placing medical devices on the Saudi market must appoint a Saudi Authorized Representative (SAR). The SAR serves as the manufacturer's legal representative in Saudi Arabia and is responsible for:

• Submitting MDMA applications and maintaining registrations with the SFDA
• Communicating with the SFDA on behalf of the manufacturer
• Receiving and forwarding SFDA notifications, inquiries, and compliance actions
• Participating in post-market surveillance and adverse event reporting
• Facilitating product recalls and field safety corrective actions
• Ensuring imported devices comply with Saudi labeling requirements (including Arabic labeling)
• Maintaining records accessible to the SFDA

The SAR must be a Saudi-registered entity (a legal person established in Saudi Arabia). The appointment is formalized through a written authorization agreement between the manufacturer and the SAR. The SFDA requires that the authorization letter be submitted as part of every MDMA application.

Practical tip: Choosing the right SAR is a critical business decision, not merely a regulatory formality. Your SAR is your face before the SFDA. They manage your registration, handle queries, and represent you in adverse event situations. Look for SARs with demonstrated regulatory expertise, SFDA relationship history, and experience with your device type. Some SARs also serve as importers and distributors, which can simplify logistics but may create conflicts of interest if they also represent competing products. Clarify exclusivity arrangements, fee structures, and service-level expectations in writing before signing.

GCC DR — Gulf Cooperation Council Device Registration

The GCC Device Registration (GCC DR) system is a regional initiative aimed at creating a single registration pathway for medical devices across all six GCC member states. In theory, a manufacturer can submit one application through the GCC DR portal and receive marketing authorization valid in all participating states.

How GCC DR Works

The GCC DR system is managed by the Gulf Health Council (GHC) and operates through a central electronic platform. The process works as follows:

1. Application submission — The manufacturer (or authorized representative) submits the registration application through the GCC DR online portal, including technical documentation, regulatory approvals, and classification information.
2. Lead reviewer assignment — The application is assigned to one of the GCC national regulatory authorities (NRAs) to serve as the lead reviewer. Lead reviewer assignment rotates among participating NRAs.
3. Technical review — The lead reviewer NRA conducts a technical assessment of the device dossier.
4. Peer review — Other participating NRAs can review the lead reviewer's assessment and provide comments.
5. Decision — Once the review is complete and accepted, the device receives GCC DR registration valid across participating states.
6. National implementation — Individual countries may require additional steps (such as local product listing or importation permits) beyond the GCC DR registration.

GCC DR Reality Check

While the GCC DR concept is sound, the practical reality as of 2026 is more nuanced:

• Saudi Arabia and the UAE are the most active participants. Their NRAs are the most developed and most frequently serve as lead reviewers.
• Parallel national requirements — Some GCC states still maintain their own national registration requirements in parallel with GCC DR. In practice, many manufacturers submit through both the GCC DR system and the national pathways to ensure market access.
• Timeline variability — GCC DR review timelines have historically been longer than some national pathways. The target review period is 90–180 days, but actual timelines can extend to 12 months or more, depending on device class and the lead reviewer's capacity.
• Not a replacement for SFDA MDMA — For the Saudi market, the SFDA's national MDMA pathway remains the primary and most reliable route. While the SFDA participates in GCC DR, many manufacturers — particularly those with FDA or EU approvals — find the SFDA's abridged MDMA pathway faster than the GCC DR route.

Practical tip: The GCC DR is useful for manufacturers seeking broad GCC market access with a single submission, particularly for lower-risk devices. However, for Saudi Arabia specifically, the national MDMA pathway is generally faster and more predictable. The recommended strategy for many manufacturers is to pursue SFDA MDMA for Saudi Arabia first (especially if you have FDA/EU approval for the abridged pathway), then use the GCC DR or national pathways for other GCC markets.

SFDA Timeline and Fees

The SFDA substantially increased its MDMA fees in late 2024. The current official fee schedule (effective January 2025, published by the SFDA as "Elevation Fees of Medical Device Marketing Authorization") is significantly higher than fees quoted in older guidance materials:

MDMA New Application Fees (by Risk Classification)

Fee Group	Risk Classification	SFDA Fee (SAR)	Approximate Fee (USD)	Lead Time
FG (1)	Class A (all sub-types)	SAR 15,000	~$4,000	35 working days
FG (2)	Class B	SAR 19,000	~$5,060	35 working days
FG (3)	Class C	SAR 21,000	~$5,600	35 working days
FG (4)	Class D	SAR 23,000	~$6,130	35 working days

MDMA Update and Renewal Fees

Type of Change	Fee Type	SFDA Fee (SAR)	Approximate Fee (USD)
MDMA Renewal	Reduced	SAR 5,000	~$1,330
Add device(s) or model(s)	Major update	SAR 5,000	~$1,330
Brand name change	Major update	SAR 5,000	~$1,330
Update technical file	Major update	SAR 5,000	~$1,330
Manufacturer name/address (minor change)	Major update	SAR 5,000	~$1,330
Update label(s) only	Administrative	SAR 1,100	~$295
Update IFU(s) only	Administrative	SAR 1,100	~$295
Update advertising materials only	Administrative	SAR 1,100	~$295
Change risk classification	Full	Full fee per new risk class	Varies
Change legal manufacturer name/address	Full	Full fee per risk class	Varies

Other SFDA Fees

Fee Category	SFDA Fee (SAR)	Approximate Fee (USD)
Classification application	SAR 1,000	~$270
Authorized Representative license (annual)	SAR 2,600	~$695
Manufacturing site audit (if required)	Variable	$5,000–$15,000+

Important context on fee increases: The SFDA's fee elevation represents a significant increase from the pre-2024 fee structure. Class A registration fees increased from SAR 500 (under the now-canceled MDNR) to SAR 15,000 under the current MDMA pathway — a 30x increase. These fees are still substantially lower than FDA user fees ($26,067 for a standard 510(k) in FY2026, $579,272 for a PMA) or EU MDR Notified Body fees (often exceeding EUR 50,000 for initial certification), but they are no longer negligible. For manufacturers bundling multiple devices, the fee applies per MDMA application (not per device), making the bundling strategy described above an important cost optimization tool.

The MDMA certificate is valid for three years from the date of issuance. Renewal applications can be submitted up to 90 days before the expiration date. Failure to renew before expiration means the manufacturer is no longer authorized to market the device in Saudi Arabia and must reapply.

Registration timelines summary:

Scenario	Typical Timeline
Class A listing	2–4 weeks
MDMA — abridged (with FDA/EU approval)	1–3 months
MDMA — standard (without reference approval)	3–6 months
MDMA — complex or novel device (Class D, no reference)	6–12+ months
GCC DR (from submission to registration)	6–12+ months

UAE: A Multi-Regulator Framework

Understanding the UAE Regulatory Landscape

The United Arab Emirates has a more complex regulatory structure than Saudi Arabia because device regulation is distributed across multiple authorities — both federal and emirate-level. Understanding which authorities govern your target market within the UAE is essential.

Major Regulatory Restructuring: The MOHAP-to-EDE Transfer (2025)

In a landmark development, the UAE completed a significant regulatory restructuring in late 2025. Under Federal Decree of Law No. 38 (effective January 2, 2025), all medical device regulatory services previously overseen by the Ministry of Health and Prevention (MOHAP) were transferred to the Emirates Drug Establishment (EDE). Created in 2023, the EDE now serves as the sole federal authority governing medical device regulation at the national level.

The nine core regulatory functions transferred from MOHAP to EDE include:

1. Device classification — Determining whether products qualify as medical devices and assigning risk class
2. Market authorization — Issuing approvals for new and renewed device registration applications
3. Import permits — Regulating entry of devices and components into the UAE
4. Manufacturer registration — Licensing production facilities and processing renewal of registrations
5. Advertising approvals — Authorizing promotional materials and labeling claims for medical devices
6. Post-market vigilance — Managing adverse event reporting and safety monitoring
7. Advertisement license renewal — Renewing previously approved promotional content
8. Side effects reporting — Collecting pharmacovigilance data on medical products
9. GMP certification — Good Manufacturing Practice certification for device manufacturing

What MOHAP retains: MOHAP continues to oversee community pharmacies, compounding pharmacies, and certain narcotics-related controls (prescription books, custody authorization, quota management, and hospital approvals). MOHAP also retains jurisdiction over health facility licensing.

Critical action for manufacturers: All medical device submissions — new applications, renewals, variations, and communications — must now be directed to the EDE portal (www.ede.gov.ae) rather than MOHAP. Companies with pending MOHAP applications or existing MOHAP registrations should confirm their status through EDE and ensure their internal procedures and regulatory team training reflect this change. UAE PASS login access and organizational profiles should be verified against the EDE system.

The key regulatory bodies are now:

Authority	Jurisdiction	Acronym	Scope
Emirates Drug Establishment	Federal (all UAE)	EDE	National device classification, market authorization, import permits, manufacturer licensing, post-market vigilance (transferred from MOHAP effective late 2025)
Ministry of Health and Prevention	Federal (all UAE)	MOHAP	Overarching health policy, community pharmacy oversight, narcotics controls; legacy medical device registrations being transitioned to EDE
Department of Health — Abu Dhabi	Emirate of Abu Dhabi	DOH	Device registration for Abu Dhabi healthcare facilities, health facility licensing, separate drug formulary
Dubai Health Authority	Emirate of Dubai	DHA	Device registration for Dubai, health facility and professional licensing
Health Authority — Abu Dhabi (now merged into DOH)	Emirate of Abu Dhabi	HAAD (legacy)	Historical reference — functions consolidated into DOH

In practice, the UAE regulatory framework operates at two levels:

1. Federal level (EDE, formerly MOHAP) — Sets the overarching regulatory framework, issues federal marketing authorizations, and manages import permits for medical devices entering the UAE. Since the 2025 transfer, EDE is the primary federal contact for all device-related regulatory matters.
2. Emirate level (DOH and DHA) — Abu Dhabi's Department of Health and Dubai's Dubai Health Authority maintain their own device registration requirements for healthcare facilities operating within their respective emirates.

This means a device sold across the entire UAE may need federal EDE registration plus emirate-level registration in Abu Dhabi (DOH) and Dubai (DHA), depending on the end customer.

EDE / MOHAP — Federal Registration

The Emirates Drug Establishment (EDE) now serves as the federal regulatory authority for medical devices, having assumed this role from MOHAP in late 2025. The medical device registration system underwent significant modernization between 2020 and 2024 under MOHAP, and this infrastructure has been carried forward into EDE. References to "MOHAP registration" in older materials now apply to EDE. Existing MOHAP device registrations remain valid and are being administratively transitioned to EDE.

MOHAP Classification

The UAE uses a four-class system (Class A, B, C, D) that is functionally identical to the SFDA and GHTF frameworks:

UAE Class	EU MDR Equivalent	Risk Level
Class A	Class I	Low
Class B	Class IIa	Low-Moderate
Class C	Class IIb	Moderate-High
Class D	Class III	High

MOHAP Registration Process

1. Establishment registration — The manufacturer (or UAE authorized representative) must first register the establishment with MOHAP. This includes submitting company documentation, quality system certificates, and authorized representative appointment letters.
2. Product registration — Submit the device registration application through MOHAP's electronic system. Required documentation includes:
   • Device description and intended use
   • Classification justification
   • ISO 13485 certificate
   • Free Sale Certificate (FSC) or Certificate of Conformity from the country of origin
   • CE certificate (if available) or FDA clearance/approval letter
   • Risk management summary (ISO 14971)
   • Biocompatibility data
   • Clinical evidence summary
   • Labeling (English and Arabic)
   • IFU in Arabic
3. Technical review — MOHAP conducts a technical review. The depth of review varies by device class.
4. Import permit — Once registered, each shipment of devices entering the UAE requires an import permit from MOHAP. The import permit references the product registration number and verifies that the incoming devices match the registered specifications.

EDE/MOHAP Timelines and Fees

Device Class	Registration Timeline
Class A	2–4 weeks
Class B	1–3 months
Class C	2–4 months
Class D	3–6+ months

The official average processing time published by MOHAP/EDE is 45 working days for a complete submission.

EDE/MOHAP Fee Schedule

Fee Category	Amount (AED)	Approximate Fee (USD)
Application fee	AED 100	~$27
Registration of a medical device	AED 5,000	~$1,360
Renewal of medical device registration	AED 2,500	~$680
Manufacturer/site registration renewal	AED 10,000+	~$2,720+

Medical device registrations in the UAE are valid for five years from the date of the last approval. Renewal applications should be initiated 3–6 months before expiration to avoid processing delays. Renewals are typically processed within approximately 15 working days once all documents are submitted and fees are paid. If registration lapses due to late renewal, the manufacturer faces suspension of import permits, blocked customs clearance, loss of distribution rights, and potential regulatory fines.

Practical tip: The Marketing Authorization Holder (MAH) applying for registration or renewal must be a medical warehouse or marketing office with a valid UAE license issued by EDE/MOHAP. Foreign manufacturers cannot submit directly — they must work through their UAE-based authorized representative who holds the appropriate establishment license.

DOH Abu Dhabi — Device Registration

The Abu Dhabi Department of Health (DOH) maintains its own medical device regulatory framework for devices used in healthcare facilities within the Emirate of Abu Dhabi. The DOH has been one of the more proactive regulators in the region, implementing structured classification, registration, and surveillance systems.

DOH Registration Process

1. Manufacturer/Supplier registration — Register the company on the DOH portal. Submit company documentation, quality certificates, and authorized representative information.
2. Product submission — Submit the device application with:
   • Completed DOH application form
   • CE certificate (EU MDR preferred) or FDA clearance/approval
   • ISO 13485 certificate
   • Free Sale Certificate
   • Device master file or technical file summary
   • Clinical data summary
   • Arabic labeling samples
   • Risk management documentation
3. Classification verification — DOH verifies the device classification.
4. Technical assessment — DOH reviews the submission. For devices with CE marking or FDA approval, the review leverages the reference authority's assessment.
5. Registration issuance — Upon approval, the device is registered in the DOH system and can be supplied to Abu Dhabi healthcare facilities.

DOH Key Requirements

• CE marking or FDA approval is strongly preferred and significantly accelerates the registration process. The DOH explicitly recognizes EU MDR CE certificates and FDA clearances/approvals as primary evidence of device safety and performance.
• Arabic labeling is mandatory for all devices marketed in Abu Dhabi.
• Local authorized representative — A UAE-based authorized representative is required.
• Post-market surveillance — The DOH requires post-market vigilance reporting, including adverse event reporting and field safety corrective action notifications.
• Registration validity — DOH device registrations are typically valid for 3–5 years, subject to renewal.

DHA Dubai — Device Requirements

The Dubai Health Authority (DHA) regulates medical devices within the Emirate of Dubai. Dubai's regulatory approach has historically been somewhat less formalized than Abu Dhabi's, but DHA has been building its device registration framework and increasing its regulatory expectations.

DHA Registration Process

1. Company registration — Register the manufacturer and/or local distributor with the DHA.
2. Product notification/registration — Submit device information to the DHA system, including:
   • Regulatory approval from a recognized reference authority (FDA, EU/CE, Health Canada, TGA)
   • ISO 13485 certificate
   • Free Sale Certificate
   • Device description and intended use
   • Classification information
   • Arabic labeling
3. Review and approval — DHA reviews the submission. For devices with recognized international approvals, the process is streamlined.
4. Registration issuance — The device is registered for use in Dubai healthcare facilities.

DHA Considerations

• Reference authority reliance — DHA places significant weight on existing approvals from FDA, EU, Health Canada, and TGA. Holding one of these approvals is effectively a prerequisite for practical DHA registration.
• Health facility licensing — DHA also licenses healthcare facilities in Dubai. Device procurement at DHA-licensed facilities typically requires that devices be registered with the DHA.
• Dubai Healthcare City (DHCC) — The DHCC free zone has its own health regulatory framework, though it generally aligns with DHA requirements.

UAE Local Authorized Representative

All foreign manufacturers marketing medical devices in the UAE must appoint a local authorized representative (UAE AR). The UAE AR fulfills similar functions to the Saudi AR:

• Submitting and maintaining device registrations with EDE (federal), DOH (Abu Dhabi), and DHA (Dubai)
• Managing import permits and customs documentation
• Serving as the regulatory point of contact within the UAE
• Handling adverse event reporting and vigilance obligations
• Ensuring Arabic labeling compliance

The UAE AR must be a UAE-registered legal entity — specifically, a medical warehouse or marketing office with a valid license issued by EDE/MOHAP. Many UAE ARs also serve as importers and distributors, providing end-to-end market access services.

Practical tip: The multi-regulator structure in the UAE can catch manufacturers off guard. Registering with EDE (federal) alone does not guarantee access to Abu Dhabi or Dubai facilities. If your target customers are hospitals in Abu Dhabi, you need DOH registration. If they are in Dubai, you need DHA registration. Many manufacturers register at all three levels — federal EDE plus DOH and DHA — to ensure UAE-wide market access. Your UAE AR should be experienced in navigating all three systems simultaneously. Note: if you encounter references to "MOHAP registration" in older materials or from other companies, this now refers to the EDE system.

Other GCC Markets

Kuwait

Kuwait's medical device regulation has undergone significant restructuring. As of 2025, medical devices and IVDs are regulated by the Medicine and Medical Products Registration and Regulatory Administration (MMPRRA) within the Kuwait Ministry of Health, established under Ministerial Decree MD (387/2025). This replaced the earlier Kuwait Drug and Food Control Administration and represents a more formalized regulatory approach.

• Registration — All medical devices and IVDs must be registered with the MOH through the MMPRRA before importation, marketing, or distribution in Kuwait, for both public and private sectors. Registration requires submission of a Summary Technical Documentation (STED) demonstrating conformity with Essential Principles of Safety and Performance for most Class B, C, and D devices.
• Classification — Kuwait uses the GHTF/GCC four-class system (A, B, C, D).
• Reference market reliance — FDA clearance or EU CE marking significantly facilitates registration. Kuwait's abridged review pathway accepts reference market approvals to streamline the process.
• Local representative — A local authorized representative or distributor is required. Only registered authorized representatives can submit device registration applications.
• GCC DR — Kuwait participates in the GCC DR system, and GCC DR registrations are recognized.
• Review tracks and timelines — Kuwait now offers multiple review tracks:
  • Standard Review: 6–9 months
  • Abridged Review (with reference market approvals): 3–6 months
  • Fast-Track Review: Case-dependent, for urgent public health needs
• Post-market requirements — Kuwait requires ongoing vigilance reporting and periodic renewal of registrations with updated documentation.

Bahrain

The National Health Regulatory Authority (NHRA) regulates medical devices in Bahrain. The NHRA has been actively modernizing its regulatory framework and is one of the most structured regulators among the smaller GCC states. In a major enforcement milestone, the NHRA announced that all medical devices must be registered before February 1, 2026, in accordance with Resolution No. 48 of 2020.

• Registration — NHRA product registration is mandatory for all medical devices regardless of risk classification (Class I, IIa, IIb, III for devices, and Class A, B, C, D for IVDs). All devices must first be listed with the NHRA before full registration can proceed. The registration process is conducted through the Ajheza electronic system — applicants book an appointment and submit all required documents at the scheduled date and time.
• Classification — Bahrain uses a classification system aligned with EU/international standards: Class I, IIa, IIb, and III for general medical devices; Class A, B, C, D for IVDs. This differs slightly from the GCC's standard A/B/C/D classification used by Saudi Arabia and the UAE.
• Reference authority recognition — NHRA explicitly recognizes approvals from Saudi Arabia (SFDA), USA (FDA), Switzerland (Swissmedic), Japan (PMDA), and other reference markets. A Quality Assurance Certificate (CE certificate under EU Directive/MDR or FDA Registration Certificate) is required for the legal manufacturer. For Class III or Class D (IVD) devices, an EC Design Examination Certificate or FDA registration certificate is required with a minimum one-year validity.
• Local representative — Only registered authorized representatives can apply for device registration. AR companies are classified into classes (A, B, C, D) based on a scoring criteria extracted from AR registration essential principles. The AR Registration Certificate is valid for a minimum of one year and must be renewed six months before expiry.
• Fast-track pathway — NHRA has recognized conformity assessment bodies (such as Medespero) to facilitate fast-track registration for applicants facing difficulties in preparing required documents. Fast-track review is completed in approximately 10 working days, compared to the standard 20 working days.
• Review timeline — Standard review takes 10–20 working days (6–8 weeks including document submission scheduling). Registration certificates are valid for one year and must be renewed with updated documentation.
• GCC DR — Bahrain participates in GCC DR and accepts GCC DR registrations.
• Notable strength — Bahrain has a reputation as one of the most efficient GCC regulators for device registration, with relatively predictable timelines and a transparent electronic submission system.

Qatar

The Ministry of Public Health (MoPH) regulates medical devices in Qatar. Qatar's regulatory system has developed rapidly, driven in part by healthcare infrastructure investments associated with Qatar National Vision 2030.

• Registration — Medical devices must be registered with MoPH. The registration system is electronic.
• Classification — Four-class system (A, B, C, D).
• Reference market reliance — CE marking or FDA approval is strongly favored.
• Local representative — Required. The local agent must be a Qatar-registered company.
• GCC DR — Qatar participates in GCC DR.
• Healthcare sector — Qatar's healthcare sector is relatively concentrated. Major institutions like Hamad Medical Corporation and Sidra Medicine are major purchasers, and their procurement processes may impose additional requirements beyond regulatory registration.

Oman

The Ministry of Health (MoH) is the regulatory authority for medical devices in Oman, with the Drug Safety Center (DSC) and specifically the Medical Device Control Department administering device registration. Oman's regulatory framework has undergone a dramatic transformation in 2025, moving from one of the least formalized GCC systems to an increasingly structured regime.

Oman's 2025 Regulatory Overhaul

In a landmark development, Oman officially launched mandatory registration for medical devices through Circular 161/2025 (issued July 2025):

• E-portal launch — A new electronic portal for medical device applications went live on August 11, 2025, replacing the previous manual submission process.

• Mandatory registration deadline — All Class C and Class D medical devices (including IVDs) must be registered by July 1, 2026. After this date, importation without registration will be restricted.

• Published guidance documents — The Oman MoH Drug Safety Center published comprehensive guidance documents in October–November 2025:

  • Guideline on Requirements of Class C & D Medical Devices Registration (GD3)
  • Guideline on Requirements of Class C & D In Vitro Diagnostic Devices Registration (GD5)
  • Guideline on Requirements of Medical Device Manufacturer Registration

• Classification system — Oman has adopted a classification system with the following structure:

  • Low Risk: Class A/B (equivalent to Class I internationally)
  • Moderate to High Risk: Class C (equivalent to Class II)
  • High Risk: Class D (equivalent to Class III)

• Registration requirements — The Oman dossier structure closely follows the IMDRF Common Submission Dossier Template (CSDT) and includes sections on: application type, manufacturer information, device information, device labeling, Essential Principles and evidence of conformity, design verification and validation summary, product verification and validation, clinical evidence, post-market control, device distribution status, and a declaration of conformity.

• Manufacturer registration — In addition to product registration, manufacturers (including international manufacturers) must complete a separate manufacturer registration through the online portal. Prerequisites include a manufacturer license (fees apply), initial approval for wholesale activity, and local medical device establishment approval if the device will be sold through a local entity.

• Reference market recognition — FDA and CE approvals facilitate registration and support the technical assessment.

• Local representative — A local Omani agent or distributor is required.

• GCC DR — Oman participates in GCC DR.

Practical tip: Oman's July 2026 mandatory registration deadline for Class C and D devices is a critical milestone for manufacturers currently supplying the Omani market. Companies that have been importing devices into Oman without formal registration under the previous less-formalized system must begin the registration process now to ensure uninterrupted market access. The new e-portal and published guidance documents provide a clear pathway, but early submission is advisable given that this is a new system and processing times may be longer as the regulator builds capacity.

GCC Market Comparison

Factor	Saudi Arabia	UAE	Kuwait	Bahrain	Qatar	Oman
Primary regulator	SFDA	EDE / DOH / DHA	MoH (MMPRRA)	NHRA	MoPH	MoH (DSC)
Classification system	A, B, C, D	A, B, C, D	A, B, C, D	I, IIa, IIb, III (devices) / A-D (IVD)	A, B, C, D	A/B, C, D
Electronic system	GHAD	EDE portal	MMPRRA portal	Ajheza	MoPH e-system	New e-portal (Aug 2025)
Market size (approx.)	~$6.5B (2025)	~$3–4B	~$800M–1B	~$300–400M	~$800M–1B	~$400–500M
Regulatory maturity	High	High (complex, restructuring)	Medium-High (reforming)	Medium-High	Medium-High	Medium (rapidly developing)
FDA/CE reliance	Independent review (supports but not required)	Very strong	Strong	Strong	Strong	Strong
Local rep required	Yes (SAR)	Yes (UAE AR)	Yes	Yes (scored AR system)	Yes	Yes
GCC DR participant	Yes	Yes	Yes	Yes	Yes	Yes
Arabic labeling	Mandatory	Mandatory	Mandatory	Mandatory	Mandatory	Mandatory
Registration validity	3 years	5 years	Periodic renewal	1 year	2–5 years	Per regulation
Typical Class B timeline	35 working days (official)	1–3 months	3–6 months (abridged)	10–20 working days	2–4 months	To be established
Key 2025–2026 development	Fee elevation, MDMA2 only	MOHAP-to-EDE transfer	MMPRRA establishment (MD 387/2025)	Mandatory registration by Feb 2026	Continued digitization	Mandatory Class C/D registration by Jul 2026

GCC Mutual Recognition

The Framework

The GCC Standardization Organization (GSO) and the Gulf Health Council (GHC) have worked to establish mutual recognition of medical device registrations across GCC member states. The goal: a device registered in one GCC country should be recognized in all others without full re-evaluation.

The GCC DR system (described above) is the operational mechanism for this mutual recognition. In principle, a device that passes GCC DR review is registered across all participating states.

Practical Limitations

Mutual recognition in the GCC remains aspirational in some respects. Practical challenges include:

• National sovereignty — Each GCC state retains the right to impose additional national requirements or to reject a device despite GCC DR registration. This rarely happens, but the possibility exists.
• Implementation gaps — Not all GCC states have fully integrated GCC DR into their national regulatory workflows. Some states still require parallel national registration.
• Capacity constraints — Smaller GCC NRAs may lack the resources to fully participate in GCC DR peer review, leading to delays.
• Import controls — Even with GCC DR registration, each country maintains its own customs and import permit requirements. GCC DR registration does not automatically grant import clearance.

Despite these limitations, the GCC DR system has improved meaningfully since its early years. For manufacturers targeting multiple GCC markets, it provides a more efficient pathway than registering individually in every country — particularly for Class A and B devices.

GSO-CEN Technical Cooperation Agreement (October 2025)

In a significant development for GCC-EU regulatory alignment, the GCC Standardization Organization (GSO), represented by the Gulf Technical Committee for Medical Devices and Supplies, signed a Technical Cooperation Agreement with the European Committee for Standardization (CEN), represented by the European Technical Committee for Non-active Medical Devices, in late October 2025.

This agreement aims to harmonize standards for medical devices including blood pressure monitors, thermometers, catheters, and other non-active devices. It is the sixth Technical Cooperation Agreement signed by the GSO to increase harmonization with European regulatory bodies — previous agreements have covered oil and gas, plastics and rubber, air conditioning equipment, and other sectors.

Practical implications for manufacturers:

• GCC technical standards for covered device categories will increasingly align with CEN/European standards, reducing the documentation burden for EU-based manufacturers entering GCC markets.
• Companies already compliant with harmonized European standards for non-active medical devices will find their existing quality and technical documentation more directly applicable to GCC registration.
• The agreement reinforces the broader trend of GCC regulatory convergence with EU MDR/IVDR standards, beyond the IMDRF alignment already pursued by the SFDA.

Comparison: GCC DR vs. EU Single Market

Aspect	GCC DR	EU Single Market (CE Marking)
Legal basis	GCC agreements, voluntary participation	EU Regulations (MDR, IVDR) — directly applicable law
Single registration	In theory, yes. In practice, national steps often still required	Yes. CE marking grants access to all 27 EU member states + EEA
Parallel national requirements	Common	Rare (some national notification requirements exist)
Enforcement mechanism	Soft — based on cooperation agreements	Strong — EU law with infringement procedures
Notified Body / single reviewer	Lead reviewer NRA model	Notified Body certification
Maturity	Developing	Mature (decades of operation)
Timeline predictability	Variable	More predictable (though Notified Body backlogs exist)

IMDRF Convergence

The International Medical Device Regulators Forum (IMDRF) has become an increasingly important influence on Middle Eastern device regulation. Saudi Arabia's SFDA is a full management committee member of IMDRF, and several IMDRF frameworks have been adopted or adapted by GCC regulators.

Key areas of IMDRF convergence in the Middle East:

• Classification — The GCC four-class system (A, B, C, D) is directly derived from the GHTF/IMDRF classification framework.

• UDI (Unique Device Identification) — The SFDA has implemented UDI requirements aligned with IMDRF UDI guidance. Saudi Arabia requires UDI on device labels and in the SFDA product registration database.

• Adverse event reporting — SFDA adverse event reporting terminology and processes align with IMDRF adverse event terminology (IMDRF/AE WG/N43).

• MDSAP recognition — The SFDA recognizes MDSAP certificates, reflecting alignment with the IMDRF MDSAP framework.

• Regulatory convergence roadmap — The SFDA has published a regulatory convergence strategy that explicitly targets alignment with IMDRF guidance documents across multiple regulatory domains.

• Essential Principles of Safety and Performance (EPSP) — The SFDA's EPSP framework (embedded in MDS-REQ 1) is closely modeled on the IMDRF Essential Principles (IMDRF/GRRP WG/N47, Edition 2, 2024). This framework requires manufacturers to demonstrate conformity with each applicable Essential Principle through a structured checklist — essentially the SFDA equivalent of the EU MDR GSPR checklist. The EPSP checklist is mandatory for all MDMA applications.

• AI/ML medical devices — The SFDA has adopted IMDRF SaMD principles (via MDS-G023 and MDS-G010) as the basis for regulating AI-enabled medical devices. The SFDA requires "valid clinical association, analytical/technical validation, and clinical validation" for AI medical devices, drawing on both IMDRF guidance and WHO standards.

• Common Submission Dossier Template (CSDT) — Several GCC regulators, including Oman's Drug Safety Center, have adopted dossier structures based on the IMDRF/AHWP Common Submission Dossier Template, facilitating documentation reuse across markets.

This convergence has practical benefits for manufacturers. Companies that are already compliant with IMDRF-aligned requirements (through FDA, EU, or other IMDRF-member regulatory submissions) will find that much of their existing documentation and quality system evidence can be leveraged for Saudi and GCC submissions.

IVD Registration Specifics

In vitro diagnostic (IVD) devices have distinct regulatory requirements across the Middle East. As IVD demand grows — driven by infectious disease testing, chronic disease management, point-of-care diagnostics, and molecular diagnostics — understanding IVD-specific requirements is increasingly important.

Saudi Arabia — SFDA IVD Requirements

The SFDA regulates IVDs under the same Medical Devices Sector that governs all medical devices. IVDs follow the same MDMA process but with IVD-specific considerations:

• Classification — IVDs are classified using the GHTF/IMDRF IVD classification rules, similar to IVDR Classes A–D:

IVD Class	Risk	Examples
Class A	Low	General lab reagents, specimen containers, wash solutions
Class B	Low-Moderate	Clinical chemistry reagents, hematology analyzers, self-testing devices (pregnancy tests)
Class C	Moderate-High	Companion diagnostics, blood glucose self-testing, tumor markers, HLA typing
Class D	High	Blood group typing (ABO, Rh), HIV/HBV/HCV screening for transfusion safety, variant CJD testing

• Performance evaluation — The SFDA requires performance evaluation data for IVDs, including analytical performance (sensitivity, specificity, precision, accuracy, linearity, measuring range) and clinical performance data. The depth of evidence required scales with device class.
• Reference standards — ISO 15189 (medical laboratory quality and competence) and relevant ISO IVD standards (e.g., ISO 18113 for IVD labeling, ISO 17511 for metrological traceability) are referenced.
• Companion diagnostics — IVDs intended to guide therapeutic decisions for specific drugs (companion diagnostics) are classified as Class C or D and require robust clinical evidence linking the diagnostic result to clinical outcomes.

UAE — IVD Requirements

In the UAE, IVD registration follows the general device registration process at all three levels (EDE at the federal level, DOH in Abu Dhabi, DHA in Dubai). Key IVD-specific considerations:

• Classification — UAE IVD classification mirrors the GHTF/GCC system.
• Performance data — EDE and DOH require analytical and clinical performance data for Class B and above IVDs.
• Laboratory accreditation context — The UAE has a strong laboratory accreditation infrastructure. Healthcare facilities using IVDs are expected to comply with ISO 15189, which influences the IVD procurement and registration process.
• Point-of-care testing (POCT) — The UAE has implemented specific guidance for POCT devices, reflecting the growing use of rapid diagnostics in primary care and pharmacy settings.

IVD-Specific Challenges in the Middle East

• Infectious disease testing — Given the region's public health priorities (including tuberculosis, hepatitis, and emerging infections), IVDs for infectious disease detection receive close regulatory scrutiny.
• Self-testing IVDs — The GCC market for consumer self-testing IVDs (glucose monitors, pregnancy tests, cholesterol tests) is growing rapidly. Regulators are implementing specific requirements for self-testing devices, including lay-user labeling and human factors considerations.
• Molecular diagnostics — PCR-based and next-generation sequencing (NGS) diagnostics are a growing segment. Regulatory frameworks for these technologies are still evolving in the Middle East, and manufacturers may encounter uncertainties in classification and evidence requirements.

Post-Market Requirements

Middle Eastern regulators — particularly the SFDA — have significantly strengthened post-market surveillance requirements in recent years, converging toward EU MDR and FDA expectations.

Saudi Arabia — SFDA Post-Market Obligations

Obligation	Description	Applicability
Adverse event reporting	Mandatory reporting of deaths, serious injuries, and malfunctions to the SFDA. Reporting timelines: 10 days for deaths and serious public health threats, 30 days for serious injuries, 30 days for malfunctions that could lead to death or serious injury.	All device classes
Field Safety Corrective Actions (FSCA)	Manufacturers must notify the SFDA and implement corrective actions for devices that present a risk. Field Safety Notices (FSNs) must be issued in Arabic and English.	All device classes
Periodic Safety Update Reports (PSUR)	Periodic reports summarizing safety data, adverse events, and risk-benefit analysis. Required annually or as specified by the SFDA.	Class C and D
Post-Market Surveillance (PMS) Plan	A documented plan describing the manufacturer's PMS system, including methods for collecting and analyzing safety data.	All device classes (depth scaled by risk)
Post-Market Clinical Follow-up (PMCF)	Ongoing clinical data collection to confirm long-term safety and performance. Required for Class C and D; recommended for Class B.	Class C and D
Registration renewal	MDMA registrations must be renewed periodically (typically every 3–5 years). Renewal requires updated safety data and confirmation of continued compliance.	All device classes

UAE — Post-Market Obligations

UAE post-market requirements are implemented at both federal and emirate levels:

• EDE vigilance reporting (formerly MOHAP) — Mandatory adverse event reporting to EDE. Specific reporting timelines apply:
  • Serious injuries and deaths: 10 days
  • Public health concerns: 48 hours
  • All other incidents: 30 days
  • High-risk devices must submit Periodic Safety Update Reports (PSURs) biannually
• DOH Abu Dhabi — DOH has implemented vigilance reporting requirements for devices sold in Abu Dhabi. Healthcare facilities are also obligated to report adverse events. The DOH issues its own Field Safety Corrective Action circulars (referencing EDE circulars) to healthcare facilities in Abu Dhabi.
• DHA Dubai — DHA requires adverse event reporting and FSCA notification for devices registered in Dubai.
• Recalls — Both EDE and emirate authorities must be notified of any product recall. Recall communications must be issued in Arabic and English.

Practical tip: Do not treat post-market surveillance in the Middle East as an afterthought. SFDA enforcement has become increasingly active, with inspections and compliance actions targeting companies that fail to report adverse events or implement FSCAs. The UAE's EDE has also structured its post-market obligations with specific reporting timelines. Ensure your vigilance system covers the Middle East with the same rigor as your FDA MDR or EU MDR post-market processes. Many manufacturers integrate Middle Eastern vigilance reporting into their global PMS system, with local ARs handling Arabic-language communications and in-country logistics.

Recent Regulatory Reforms

The Middle Eastern regulatory landscape has undergone significant changes in recent years. Understanding these reforms is essential for manufacturers planning market entry or managing existing registrations.

Saudi Arabia — Key Reforms

1. SFDA Medical Devices Law (2021) — Saudi Arabia enacted a comprehensive Medical Devices Law that provides the legal foundation for SFDA's authority over device registration, manufacturing, importation, distribution, advertising, and post-market surveillance. This law replaced earlier, more fragmented regulations and provides a modern statutory framework.

2. Electronic system modernization (GHAD platform) — The SFDA transitioned all device registration to the GHAD electronic system, streamlining submissions, tracking, and communications. The platform supports online application submission, document upload, status tracking, and fee payment.

3. UDI implementation — The SFDA has phased in UDI requirements, beginning with Class D devices and extending to all classes. Manufacturers must include UDI on device labels and register UDI data in the SFDA database. The SFDA's UDI system is aligned with IMDRF guidance and accepts GS1 and HIBCC issuing agency codes.

4. IMDRF alignment — The SFDA's elevation to full IMDRF management committee member has accelerated regulatory convergence. The SFDA has adopted or adapted multiple IMDRF guidance documents covering classification, UDI, adverse event terminology, and software as a medical device.

5. Local manufacturing incentives — Saudi Arabia is actively incentivizing local medical device manufacturing as part of Vision 2030. Programs include tax incentives, co-investment funds, and streamlined licensing for manufacturers establishing production facilities in the Kingdom. The SFDA has introduced expedited registration pathways for locally manufactured devices.

6. Clinical trial regulation — The SFDA has established a clinical trial regulatory framework for medical devices (MDS-REQ 2), including requirements for clinical investigation applications, ethics committee approval, and Good Clinical Practice compliance.

7. Digital health regulation (MDS-G27, August 2025) — The SFDA released comprehensive guidance on Digital Health Products (MDS-G27, Version 1.0) in August 2025, marking a major milestone in regulating digital health technologies in Saudi Arabia. The guidance covers:

   • Software as a Medical Device (SaMD) — software intended for medical purposes that functions independently without being part of hardware
   • Mobile Health Applications (mHealth apps) — apps on smartphones, tablets, or wearables supporting healthcare functions
   • Digital Therapeutics (DTx) — evidence-based therapeutic interventions driven by software
   • Health Information Technology (HIT) — systems for managing health data
   • Telemedicine — technologies enabling remote healthcare delivery
   • Wearable Devices — health-monitoring wearable technologies
   • Virtual Reality & Augmented Reality (VR/AR) — immersive technologies used in clinical contexts
   • Artificial Intelligence and Machine Learning (AI/ML) — AI-enabled diagnostic and clinical decision support tools
   • General Wellness Devices — clearly distinguished from regulated medical devices

   The guidance provides criteria for determining when digital health products qualify as regulated medical devices requiring MDMA versus general wellness products exempt from registration. This is particularly important as Saudi Arabia's Vision 2030 digital health strategy drives rapid adoption of health technology across the Kingdom.

8. General wellness device guidance (MDS-G25, March 2025) — A companion guidance clarifying when health-related devices are considered general wellness products (not requiring MDMA) versus medical devices.

9. Innovative medical device pathway (MDS-G002) — The SFDA established a dedicated pathway for innovative medical devices, comprising a Pre-Submission Assessment stage (free of charge, providing continuous feedback during technical file preparation) and a Priority Assessment stage for Marketing Authorization (priority queue for MDMA review). Devices must meet the Essential Principles for Safety and Performance and satisfy SFDA innovative device designation criteria.

10. Combination products guidance — The SFDA has issued guidance on how to classify and regulate combination products (drug-device or biologic-device combinations), clarifying the regulatory pathway based on the primary mode of action.

11. SFDA guidance document system — The SFDA has built an extensive library of guidance documents covering specific device types and regulatory processes, including:

    • MDS-REQ 1: Requirements for Medical Devices Marketing Authorization (the core MDMA requirements document)
    • MDS-REQ 7: Requirements for Unique Device Identification (UDI)
    • MDS-REQ 10: Requirements for Inspections and Quality Management System
    • MDS-G010: Guidance on Clinical Evaluation of AI Medical Devices
    • MDS-G023: Guidance on Software as a Medical Device
    • MDS-G025: Guidance on General Wellness Devices
    • MDS-G027: Guidance on Digital Health Products
    • Guidance on labeling and packaging requirements
    • Guidance on surgical sutures
    • Guidance on biotechnology-based medical devices

UAE — Key Reforms

1. MOHAP-to-EDE transfer (2025) — The most significant UAE regulatory development in recent years. All medical device regulatory services — classification, market authorization, import permits, manufacturer licensing, advertising approvals, and post-market vigilance — transferred from MOHAP to the Emirates Drug Establishment (EDE) under Federal Decree of Law No. 38 (effective January 2, 2025). EDE, created in 2023, now serves as the sole federal authority for medical device regulation. This restructuring consolidates federal device regulatory functions under a dedicated agency, similar to how the SFDA operates as a standalone authority in Saudi Arabia.

2. Abu Dhabi DOH regulatory framework — The DOH has published comprehensive medical device guidance documents, including classification guidance, registration procedures, and post-market vigilance requirements. The DOH continues to maintain its own separate device registration system and drug formulary for the Abu Dhabi emirate, operating independently from the federal EDE system.

3. Dubai DHA expansion — DHA has expanded its device regulatory function beyond simple import control to a more structured registration and surveillance system.

4. Federal-emirate coordination — Ongoing efforts to harmonize requirements between EDE, DOH, and DHA. The EDE transfer may ultimately facilitate greater federal-emirate coordination by providing a single federal counterpart for emirate-level regulators, but the multi-regulator structure remains.

5. Post-market surveillance strengthening — The UAE has implemented more structured adverse event reporting timelines:

   • Serious injuries and deaths: 10 days
   • Public health concerns: 48 hours
   • All other incidents: 30 days
   • High-risk devices are required to submit Periodic Safety Update Reports (PSURs) biannually

GCC-Wide Reforms

1. GCC DR platform upgrade — The GCC DR electronic platform has been modernized, with improved user interface, document management, and reviewer collaboration tools.

2. Harmonized classification — All GCC states have formally adopted risk-based classification systems, though implementation details vary. Saudi Arabia and UAE use the A/B/C/D system; Bahrain uses a hybrid I/IIa/IIb/III (devices) and A/B/C/D (IVDs) system; Oman uses A/B, C, D. While the underlying GHTF/IMDRF principles are consistent across all GCC states, manufacturers should verify classification in each target market rather than assuming equivalence.

3. Convergence with international standards — GCC regulatory requirements have increasingly converged with ISO 13485, ISO 14971, IEC 62304, and other international standards, reducing the documentation burden for manufacturers already compliant with these standards.

4. GSO-CEN Technical Cooperation Agreement (October 2025) — The GCC Standardization Organization and the European Committee for Standardization signed a formal cooperation agreement on medical device standards, specifically targeting non-active medical devices. This is the most concrete step yet toward formal GCC-EU standards harmonization for medical devices.

5. National regulatory system development — Several GCC states have made major strides in formalizing their national regulatory systems:

   • Kuwait: Establishment of the MMPRRA under Ministerial Decree MD (387/2025), with structured review tracks and STED requirements
   • Bahrain: NHRA mandatory registration deadline of February 2026, Ajheza electronic system, and fast-track pathway through recognized conformity assessment bodies
   • Oman: Launch of electronic registration portal (August 2025), publication of comprehensive guidance documents (October–November 2025), and mandatory registration deadline for Class C/D devices by July 2026
   • Qatar: Continued digitization of the MoPH registration system and alignment with GCC harmonization efforts

Middle East vs. FDA and EU: Comparative Framework

Manufacturers with existing FDA or EU approvals often want to understand how Middle Eastern requirements compare. The following table provides a high-level comparison.

Regulatory Dimension	FDA (US)	EU MDR	SFDA (Saudi Arabia)	UAE (EDE)
Classification system	3 classes (I, II, III)	4 classes (I, IIa, IIb, III)	4 classes (A, B, C, D) with sub-classes	4 classes (A, B, C, D)
Primary premarket pathway	510(k), De Novo, PMA	Conformity assessment + CE marking	MDMA 2 (Technical File Application)	EDE product registration (formerly MOHAP)
Quality system standard	QMSR (21 CFR 820, transitioning to ISO 13485-aligned)	ISO 13485 (via Notified Body)	ISO 13485	ISO 13485
Clinical evidence burden	Varies by pathway; 510(k) may require minimal data	High — CER mandatory for all classes	Moderate-High — independent review; EPSP checklist mandatory	Moderate — leverages reference approvals
Local representative	US Agent (for foreign manufacturers)	EU Authorized Representative	Saudi Authorized Representative (SAR)	UAE Authorized Representative
UDI required	Yes (phased implementation complete)	Yes (phased, linked to EUDAMED)	Yes (phased implementation)	Planned / partial
Post-market surveillance	MDR (21 CFR 803), annual reports for PMA	Extensive — PMS plan, PSUR, PMCF	Expanding — adverse event reporting, PSUR for Class C/D	Structured — adverse event reporting with defined timelines (10/30 days), biannual PSUR for high-risk
Fees (typical)	High ($26K for 510(k), $579K for PMA)	High (NB fees: €50K–€300K+)	Moderate (SAR 15K–23K / $4K–$6.1K per MDMA)	Low-Moderate (AED 5,100 / ~$1,390 per registration)
Review timeline	90 days (510(k)) to 12–18 months (PMA)	6–18+ months (NB capacity dependent)	35 working days (official target)	45 working days (official average)
Registration validity	Indefinite (annual establishment registration)	Certificate validity set by NB (typically 5 years max)	3 years	5 years
Language requirements	English	EU official languages (member state dependent)	English and Arabic	English and Arabic
Regulatory maturity	Very high	Very high	High and growing	High (restructuring toward single federal authority)

Key Strategic Implications

1. Reference authority leverage — with an important caveat — Holding FDA clearance/approval or EU MDR CE marking remains a strong strategic advantage for Middle Eastern registration. UAE regulators (EDE, DOH, DHA) treat these as strong evidence of device safety and performance. However, the SFDA's transition to MDMA 2 means that FDA/EU approvals no longer enable a truly abbreviated pathway — they support and strengthen the application but do not substitute for a complete SFDA technical file. Manufacturers should understand this distinction when planning their SFDA registration strategy.

2. Documentation reuse — Technical documentation prepared for FDA or EU submissions can be substantially reused for SFDA and UAE submissions. The SFDA's EPSP checklist closely mirrors the EU MDR GSPR checklist, and the overall technical file structure follows IMDRF CSDT principles. Manufacturers should design their regulatory documentation from the outset to serve multiple markets — avoid FDA-only or EU-only formatting that makes cross-filing difficult.

3. Arabic language — The Arabic labeling and IFU requirement is non-negotiable across the Middle East. Build Arabic translation into your regulatory timeline and budget from the start, not as an afterthought.

4. Fee landscape has changed — SFDA fees are no longer negligible. At SAR 15,000–23,000 per MDMA application ($4,000–$6,130), they represent a meaningful cost — particularly for manufacturers with large product portfolios. The bundling strategy (up to 50 devices per MDMA) is an important cost optimization tool. UAE fees remain lower (AED 5,100 per registration, approximately $1,390). Total market entry costs — including AR fees, Arabic translation, and in-country logistics — can add up to $20,000–50,000+ per market depending on portfolio size and device complexity.

Market Size and Growth

The Middle East medical device market is among the fastest-growing globally. Understanding market dynamics helps manufacturers prioritize regulatory investments.

Market Overview

Market Metric	Value (2025 Estimates)	Source Context
GCC medical device market	$10.7–15.3 billion	Fortune Business Insights ($10.7B for GCC within MEA); Market Research Future ($15.3B)
Saudi Arabia	$6.5 billion (2025), projected $9.1B by 2032	PS Market Research; Saudi Arabia accounts for ~60% of GCC healthcare expenditure
Saudi Arabia (broader estimate)	$13.5 billion (2025), projected $25.7B by 2034	Report Cube (broader market definition including services)
UAE	$3–4 billion	Multiple industry estimates
Other GCC (Kuwait, Qatar, Bahrain, Oman)	$2.5–3.5 billion combined	Industry estimates
Annual growth rate	5–7.4% CAGR (depending on definition)	PS Market Research (5% CAGR); Report Cube (7.4% CAGR)
GCC connected medical devices & wearables	Growing at ~20% CAGR (2025–2030)	MarkNtel Advisors
GCC medical tourism	Projected to reach $20 billion by 2026	Market Research Future
Import dependency	>80% of devices are imported	Industry consensus
Top source countries	US, Germany, Japan, China, South Korea	Import data analysis
Saudi healthcare budget (2025)	SAR 260 billion ($69 billion) for health and social development	Saudi government budget announcement
Global medical device market context	$678.9 billion (2025), projected $1.2 trillion by 2035	Precedence Research

A note on market size estimates: Medical device market size figures for the GCC vary significantly across research firms depending on how "medical devices" are defined (narrow definition covering only devices, versus broader definitions including associated services, digital health, and consumables). The figures above represent a range of credible estimates. What is consistent across all sources is the direction: the GCC medical device market is growing significantly faster than mature markets in North America and Europe, driven by the factors described below.

Growth Drivers

• Government healthcare investment — Saudi Vision 2030 has committed massive resources to healthcare transformation, including 38 new hospitals, 75 primary healthcare centers, and expansions to existing facilities. The Saudi government allocated SAR 260 billion ($69 billion) to health and social development in 2025, maintaining consistent investment levels. The UAE is similarly investing in world-class healthcare infrastructure under its Operation 300bn industrial development strategy, which identifies medical devices as a priority sector.
• Chronic disease prevalence — The GCC has among the highest diabetes prevalence rates globally (approximately 18–24% adult prevalence in Saudi Arabia and the UAE). Cardiovascular disease, obesity, and cancer rates are also rising. This drives demand for diagnostics, monitoring devices, implants, and therapeutic technologies.
• Medical tourism — The UAE (particularly Dubai and Abu Dhabi) has positioned itself as a medical tourism hub, attracting patients from across the Middle East, Africa, and South Asia. The GCC medical tourism market is projected to reach $20 billion by 2026. Cleveland Clinic Abu Dhabi, Sidra Medicine, and similar world-class institutions drive demand for high-end medical technologies.
• Digital health adoption — Telemedicine, remote monitoring, and AI-assisted diagnostics are being adopted rapidly. Saudi Arabia's digital health strategy and the UAE's Health 2050 initiative both emphasize technology-enabled care. Saudi Arabia's national platforms NPHIES (health insurance) and Wasfaty (e-prescriptions) are digitizing care coordination at scale, while the UAE's Malaffi unified health record system enables data-driven care.
• Local manufacturing push — Both Saudi Arabia and the UAE are aggressively incentivizing local medical device manufacturing to reduce import dependency. Saudi Arabia's National Industrial Development and Logistics Program (NIDLP) and the UAE's Ministry of Industry and Advanced Technology have identified medical device manufacturing as a strategic priority. The Saudi Industrial Development Fund and the Saudi Authority for Industrial Cities provide direct financial incentives for manufacturers establishing local production facilities.
• Population growth — The GCC population is young and growing, with increasing healthcare utilization per capita.
• Genomics and precision medicine — The GCC genomics data analytics market, valued at $1.2 billion, is growing rapidly, driven by national programs such as the Saudi National Biotechnology Strategy and the UAE Genome Program. The UAE genomics market alone is expected to expand at a 13.4% CAGR, reaching $236.5 million in 2026.

Market Segments by Device Category

Device Category	Market Share (Approx.)	Key Drivers
Diagnostic imaging	20–25%	Hospital expansion, screening programs
Consumables and disposables	15–20%	Volume-driven by hospital activity
Orthopedic devices	10–12%	Aging population, trauma care
Cardiovascular devices	10–12%	High CVD prevalence, interventional cardiology growth
IVD / diagnostics	10–12%	Infectious disease testing, chronic disease management
Dental devices	5–8%	Growing dental care sector
Surgical instruments	5–8%	Hospital expansion, surgical volume growth
Digital health / SaMD	3–5%	Rapidly growing, government policy support
Other	10–15%	Ophthalmic, respiratory, rehabilitation, etc.

Tips for Foreign Manufacturers

Market Entry Strategy

1. Start with Saudi Arabia or the UAE. These are the two largest markets and have the most developed regulatory systems. Saudi Arabia's SFDA provides a predictable, well-documented pathway — particularly for manufacturers with FDA or EU approvals. The UAE offers access to a sophisticated healthcare market with strong purchasing power.

2. Prepare a complete technical file — reference approvals help but are not sufficient. This is the single most important lesson from the SFDA's 2022 transition to MDMA 2. While FDA clearance or EU MDR CE marking still significantly strengthens your SFDA and UAE applications, the SFDA now conducts an independent review of your full technical file. Manufacturers must prepare a complete Saudi-specific technical file including EPSP checklist, regardless of existing reference approvals. For the UAE (EDE, DOH, DHA), reference approvals remain the primary basis for assessment and significantly accelerate registration.

3. Choose your local representative carefully. The SAR in Saudi Arabia and the UAE AR are not passive mailboxes. They manage your regulatory submissions, handle government communications, navigate customs and import logistics, and represent you in compliance situations. The quality of your local representative directly impacts your time to market and your ongoing compliance posture. Evaluate potential representatives on:

   • Regulatory expertise and SFDA/EDE relationship history
   • Experience with your specific device type
   • Track record of registration timelines
   • Warehousing and distribution capabilities (if bundled)
   • Conflict checks (do they represent competitors?)
   • Service-level commitments and fee transparency

4. Budget for Arabic translation early. Arabic labeling and instructions for use are mandatory in every GCC market. Professional medical Arabic translation requires subject matter expertise — not general-purpose translation services. Budget $3,000–$15,000 per device family for complete Arabic translation of labeling, IFU, and patient-facing materials, depending on complexity.

5. Plan for multi-authority registration in the UAE. If your target market includes hospitals in both Abu Dhabi and Dubai, plan for EDE (federal) plus DOH (Abu Dhabi) plus DHA (Dubai) registration. Note the recent MOHAP-to-EDE transfer — all federal submissions now go through EDE, not MOHAP. Your UAE AR should manage all three levels simultaneously. The costs and timelines are manageable but must be accounted for in your market entry plan.

6. Leverage the GCC DR for smaller markets. For manufacturers targeting all six GCC states, the GCC DR can provide efficiencies — particularly for Class A and B devices. However, for Saudi Arabia specifically, the national SFDA pathway is usually faster and more predictable.

7. Budget for SFDA fee increases. The SFDA's fee elevation (effective 2024/2025) has significantly increased registration costs. For manufacturers with large product portfolios, the bundling strategy (up to 50 devices per MDMA application) is an essential cost optimization tool. Factor in SAR 15,000–23,000 per MDMA application, plus AR fees (SAR 2,600/year), translation costs ($3,000–$15,000 per device family), and potential update/renewal fees when building your market entry budget.

8. Monitor the smaller GCC markets closely. Kuwait, Bahrain, Oman, and Qatar have all undergone significant regulatory changes in 2025–2026. Oman's mandatory Class C/D registration deadline (July 2026) and Bahrain's mandatory registration enforcement (February 2026) are particularly urgent for manufacturers currently supplying these markets without formal registration. These are no longer "minimal regulation" markets.

9. Build regulatory intelligence. Middle Eastern regulatory requirements are evolving faster than in almost any other region globally. Requirements that were current 12 months ago may have fundamentally changed — the MOHAP-to-EDE transfer, SFDA fee elevation, and Oman's regulatory overhaul are recent examples. Maintain ongoing contact with your local representatives, subscribe to SFDA and EDE regulatory updates, monitor the SFDA's guidance document series (MDS-G and MDS-REQ), and attend regional medtech conferences (Arab Health in Dubai, Global Health Exhibition in Riyadh) to stay current.

Common Mistakes to Avoid

Mistake	Consequence	Prevention
Assuming FDA/CE approval alone is sufficient for SFDA registration	Application rejected or significantly delayed; SFDA requires full technical file under MDMA 2 since Jan 2022	Prepare a complete SFDA-specific technical file including EPSP checklist, regardless of existing approvals
Using outdated MDMA 1 / MDNR pathway information	Submission through non-existent pathway; wasted preparation time	Confirm current SFDA requirements — only MDMA 2 (TFA) exists since Jan 2022; MDNR canceled Sept 2022
Treating Arabic labeling as an afterthought	Registration delays, rejection of submissions	Budget and plan for Arabic translation from project start
Choosing the cheapest local representative	Poor regulatory outcomes, communication breakdowns, compliance risks	Evaluate on capability, not cost. Check references.
Submitting to MOHAP instead of EDE for UAE federal registration	Application misdirected; delays	All UAE federal medical device submissions now go through EDE (since late 2025), not MOHAP
Assuming EDE/MOHAP registration covers all of UAE	Devices blocked from Abu Dhabi or Dubai hospitals	Register at federal (EDE) and emirate levels (DOH, DHA)
Ignoring post-market surveillance requirements	SFDA enforcement actions, product withdrawal risk	Implement PMS from day one, include Middle East in global vigilance system
Submitting incomplete documentation	Repeated requests for information, significant delays	Use the SFDA's published checklists (MDS-REQ 1). Submit complete dossiers including EPSP checklist.
Assuming GCC DR replaces national registration	Market access gaps in individual countries	Confirm national requirements for each target market
Underestimating SFDA fees	Budget shortfall; registration delayed	Budget SAR 15,000–23,000 per MDMA application (not the older SAR 3,000–8,000 figures)
Ignoring smaller GCC market registration deadlines	Loss of market access in Oman (Jul 2026), Bahrain (Feb 2026), Kuwait	Monitor regulatory deadlines in all target markets; begin registration well in advance

Practical Timeline: FDA-Cleared Device to Saudi Market

For a manufacturer with an existing FDA 510(k) clearance (Class II device), the following is a realistic timeline for Saudi SFDA registration:

Phase	Activity	Timeline
Month 1	Select and contract Saudi Authorized Representative. Gather documentation: FDA clearance letter, 510(k) summary, ISO 13485 certificate, technical file, risk management file.	2–4 weeks
Month 1–2	Prepare Arabic labeling and IFU. Complete SFDA application form. Compile SFDA-specific documentation requirements.	2–4 weeks
Month 2–3	SAR submits MDMA application through SFDA GHAD portal (abridged pathway).	1 week
Month 3–5	SFDA review. Respond to any information requests (typically 1–2 rounds).	1–3 months
Month 5–6	MDMA approval issued. Device listed in SFDA database. Import permits initiated.	2–4 weeks
Total	5–6 months from project start to market

For devices without FDA or EU approval, add 2–4 months for the standard (non-abridged) review pathway.

Halal Certification Considerations

Halal certification for medical devices is a topic that generates significant confusion among foreign manufacturers. Here is what you need to know.

When Halal Certification Matters

Halal certification is not generally required for medical devices in Saudi Arabia, the UAE, or other GCC markets. The SFDA and UAE regulators do not mandate halal certification as part of the medical device registration process. Medical device registration is governed by safety, performance, and quality requirements — not halal compliance per se.

However, halal considerations become relevant in specific circumstances:

• Animal-derived materials — Devices that contain or are manufactured using materials derived from animals (particularly porcine-derived materials) may raise halal concerns. Examples include porcine-derived gelatin in wound dressings, porcine-derived heparin coatings on catheters, animal-derived collagen in tissue matrices, and bovine-derived bone graft materials. The SFDA requires manufacturers to declare the biological origin of materials used in medical devices. If porcine-derived materials are used, manufacturers should be prepared to provide justification that no halal-compliant alternative exists and that the material undergoes sufficient transformation (istihalah) during manufacturing.
• Surgical sutures — Certain absorbable sutures derived from animal intestines (catgut sutures) may trigger halal concerns. Synthetic alternatives are generally preferred in GCC markets.
• Implantable devices with biological components — Devices incorporating human or animal tissue, extracellular matrices, or biological coatings require careful documentation of material origin.

Practical Approach

1. Document material origins. As part of your technical file, clearly identify any animal-derived materials and their species of origin.
2. Disclose porcine content. If your device contains porcine-derived materials, proactive disclosure is essential. Some hospitals and surgeons in the GCC will not use porcine-containing devices regardless of regulatory status.
3. Consider alternatives. Where feasible, offering device variants that avoid porcine-derived materials can expand your addressable market in the Middle East.
4. Halal certification is available but optional. Organizations such as the Islamic Food and Nutrition Council of America (IFANCA) and Gulf-based halal certification bodies offer halal certification for medical devices. Obtaining certification is voluntary but can be a commercial advantage for devices where material origin is a concern.
5. Labeling transparency. Include material origin declarations on device labeling. GCC hospitals and purchasing committees may require this information during procurement evaluation.

Practical tip: For most medical devices — electronic instruments, imaging equipment, surgical tools, software, disposables without animal-derived materials — halal certification is a non-issue. Focus your attention on this topic only if your device contains animal-derived materials. If it does, address material origin proactively in your technical documentation and labeling rather than waiting for a regulator or customer to raise the question.

Middle East Regulatory Landscape: Summary Table

Requirement	Saudi Arabia (SFDA)	UAE (EDE/DOH/DHA)	Kuwait (MMPRRA)	Bahrain (NHRA)	Qatar (MoPH)	Oman (MoH/DSC)
Classification	A (incl. sterile/measuring/reusable), B, C, D	A, B, C, D	A, B, C, D	I, IIa, IIb, III / A-D (IVD)	A, B, C, D	A/B, C, D
Premarket pathway	MDMA 2 (TFA)	EDE product registration + DOH/DHA	MMPRRA registration (STED-based)	NHRA registration (Ajheza system)	Product registration	Electronic registration (new portal)
ISO 13485 required	Yes	Yes	Yes	Yes	Yes	Yes
FDA/CE recognition	Supports but not required (independent review)	Yes (strong reliance)	Yes (abridged pathway)	Yes (multiple reference markets)	Yes	Yes
Free Sale Certificate	Required	Required	Required	Required	Required	Required
Local AR required	Yes (SAR)	Yes (UAE AR)	Yes	Yes (scored AR classes A-D)	Yes	Yes
Arabic labeling	Mandatory	Mandatory	Mandatory	Mandatory	Mandatory	Mandatory
UDI	Required (phased)	Planned	Planned	Planned	Planned	Planned
Clinical evidence	Scaled by class; EPSP checklist mandatory	Scaled by class	STED required for Class B+	Scaled by class	Scaled by class	Required for Class C/D
Adverse event reporting	Mandatory (10/30 day timelines)	Mandatory (10/30/48h timelines)	Mandatory	Mandatory	Mandatory	Mandatory
Registration validity	3 years	5 years	Periodic renewal	1 year	2–5 years	Per regulation
Electronic submission system	GHAD	EDE portal	MMPRRA portal	Ajheza	MoPH e-system	New e-portal (Aug 2025)
GCC DR	Participating	Participating	Participating	Participating	Participating	Participating
MDMA/registration fee	SAR 15,000–23,000 ($4K–$6.1K)	AED 5,100 (~$1,390)	Varies	Fees via Ajheza	Varies	Fees apply
Typical total cost (incl. AR, translation)	$8,000–$25,000+	$5,000–$25,000+	$3,000–$15,000+	$2,000–$10,000+	$3,000–$15,000+	$2,000–$10,000+

Looking Ahead

The Middle Eastern medical device regulatory landscape is at an inflection point. Several trends will shape the next three to five years:

Continued SFDA maturation and independent review. The SFDA's transition from the GHTF-reliance model (MDMA 1) to full independent technical file review (MDMA 2) marks a deliberate trajectory toward regulatory sovereignty. Expect increasing sophistication — more detailed guidance documents (the MDS-G series is growing rapidly), stricter enforcement, expanded UDI requirements, and more rigorous post-market surveillance. The SFDA's fee increases also signal an authority investing in its own review capacity rather than relying on other regulators' assessments. Manufacturers should welcome this: a predictable, well-documented regulatory system is easier to navigate than an opaque one, even if the requirements are demanding.

UAE regulatory restructuring. The transfer of medical device regulatory functions from MOHAP to EDE is the most significant UAE regulatory development in years. In the short term, manufacturers face operational adjustments — portal migrations, updated procedures, and new compliance contacts. In the medium term, the EDE consolidation could facilitate greater harmonization with emirate-level regulators (DOH, DHA), potentially moving toward a more unified national system. However, the multi-regulator structure remains for now. Manufacturers entering the UAE market should build relationships at all regulatory levels — federal EDE plus DOH and DHA — while monitoring consolidation developments.

GCC-wide regulatory formalization. The most striking trend across the GCC is the rapid formalization of previously informal or minimal regulatory systems. Oman's launch of mandatory Class C/D device registration (July 2026 deadline), Bahrain's NHRA mandatory registration enforcement (February 2026), and Kuwait's MMPRRA establishment represent a step-change in the regulatory expectations facing manufacturers across the region. Companies that have historically sold into these markets with minimal regulatory overhead must now invest in formal registration or risk losing market access.

GCC DR and standards harmonization. The GCC DR system will continue to evolve. The GSO-CEN Technical Cooperation Agreement (October 2025) represents a concrete step toward formal GCC-EU standards alignment, which should eventually make GCC DR more efficient for manufacturers already compliant with harmonized European standards. However, full mutual recognition — where a single registration truly replaces all national requirements — is still several years away.

Digital health regulation. The SFDA's release of MDS-G27 (Digital Health Products guidance) in August 2025 marks a turning point. SaMD, AI-enabled diagnostics, digital therapeutics, mHealth apps, and wearable devices now have a defined regulatory pathway in Saudi Arabia. The UAE is developing parallel frameworks. Manufacturers of digital health products should engage with regulators early — the regulatory landscape for these technologies is evolving rapidly, and early engagement can help shape expectations and avoid surprises. The GCC connected medical devices and wearables market is growing at approximately 20% CAGR, making this a commercially significant opportunity with an increasingly defined regulatory pathway.

Local manufacturing. Saudi Arabia's Vision 2030 includes explicit targets for local medical device manufacturing. The UAE's Operation 300bn industrial strategy similarly prioritizes medical device manufacturing. Manufacturers that establish production facilities in either country may benefit from expedited registration, government procurement preferences, and financial incentives. The SFDA has introduced dedicated pathways for locally manufactured devices, and both countries are investing in pharmaceutical formulation, fill-finish operations, and medical device assembly capacity to reduce import dependency.

Convergence with global standards. The broader trend across the Middle East is convergence with international regulatory standards. This is good news for manufacturers already compliant with ISO 13485, ISO 14971, IEC 62304, and other globally recognized standards. The documentation and quality system investments you make for FDA or EU compliance increasingly translate directly to Middle Eastern market access. The SFDA's EPSP framework, the adoption of IMDRF CSDT dossier structures across the GCC, and the GSO-CEN cooperation agreement all reinforce this convergence trajectory.

The manufacturers that will succeed in the Middle East are those that treat the region not as a secondary market with lower regulatory expectations, but as a strategically important and increasingly sophisticated regulatory environment that rewards early engagement, thorough documentation, and strong local partnerships.